The FDA approved approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo/AstraZeneca) for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a trastuzumab-based regimen. Read More…
The FDA approved margetuximab-cmkb (Margenza, MacroGenics) in combination with chemotherapy for the treatment of adults with metastatic HER2-positive breast cancer who have received two or more anti-HER2 regimens, at least one of which was for metastatic disease. Read More…
The ongoing fallout of the COVID-19 pandemic has been fierce, and cancer patients have been affected in myriad ways. From a higher risk for SARS-CoV-2 infection and severe COVID-19 disease to a population-level reduction in screening and surveillance, outcomes for cancer patients have worsened during the pandemic. Read More…
Research in the Journal of Clinical Oncology found an association between the combination of daratumumab, lenalidomide, and dexamethasone with improved patient-reported outcomes versus lenalidomide and dexamethasone alone. Compared with lenalidomide (Revlimid) and dexamethasone (Rd) alone, the combination with the addition of daratumumab (Darzalex) (D-Rd) for the treatment of transplant-ineligible, newly Read more…
A new study supports exhausting noninvasive methods to diagnose hepatocellular carcinoma (HCC) before attempting biopsy. In an analysis of data from the National Cancer Database, overall survival (OS) was lower in HCC patients who underwent preoperative tissue diagnosis compared with those with a clinical diagnosis. Read More…
The FDA approved tepotinib (Tepmetko, EMD Serono) following priority review for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal–epithelial transition exon 14 (METex14) skipping alterations. Tepotinib is the first and only FDA-approved MET inhibitor that offers once-daily oral dosing. Read More…
The FDA approved a new indication for niraparib (Zejula, GlaxoSmithKline), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, as a monotherapy maintenance treatment for women with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, regardless of biomarker Read more…
A new study found that alcohol consumption accounts for a considerable portion of cancer incidence and mortality in all 50 states and the District of Columbia. Farhad Islami, MD, PhD, and his colleagues at the American Cancer Society (ACS) estimated contemporary proportions and counts of alcohol-attributable cancer cases and deaths for Read more…
The FDA approved a new indication for the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy), both made by Bristol-Myers Squibb: first-line treatment of adults with malignant pleural mesothelioma (MPM) that cannot be removed by surgery. This is the first drug regimen approved for mesothelioma in 16 years and the second approved Read more…
Researchers investigate why some patients respond exceptionally well to cancer treatment, and the Food and Drug Administration approves a second immunotherapy drug for some breast cancer patients. Read More…